Arega Balew, Wolde-Amanuel Yimtubezinash, Adane Kelemework, Belay Ezra, Abubeker Abdulaziz, Asrat Daniel
College of Health Sciences, Debremarkos University, P.O.Box 269, Debremarkos, Ethiopia.
Department of Microbiology, Immunology & Parasitology, School of Medicine, College of Health Sciences, Addis Ababa University, Churchill Avenue, P.O. Box 9086, Addis Ababa, Ethiopia.
Infect Agent Cancer. 2017 Jul 11;12:40. doi: 10.1186/s13027-017-0150-9. eCollection 2017.
In recent years, saprophytic bacteria have been emerging as potential human pathogens causing life-threatening infections in patients with malignancies. However, evidence is lacking concerning such bacteria, particularly in sub-Saharan countries. This study was designed to determine the spectrum and drug resistance profile of the rare bacterial pathogens causing bloodstream infections (BSIs) in febrile cancer patients at a referral hospital in Ethiopia.
Between December 2011 and June 2012, blood samples were collected from 107 patients with cancer in Tikur Anbessa hospital. Culturing was performed using the blood culture bottles and solid media and the microorganisms were identified using the gram staining and APINE identification kits (Biomerieux, France). The disk diffusion method was used for the antimicrobial susceptibility testing.
Overall, 13 (12.2%) rare human pathogens were isolated from 107 adult febrile cancer patients investigated. species (a fermentative gram-negative rod) was the predominant isolate, 30.8% (4/13), followed by 15.4% (2/13), 15.4% (2/13), 15.4% (2/13). Of the nine isolates tested for a nine set of antibiotics, 89% were resistant to amoxicillin-clavulanic acid, ampicillin, and trimethoprim-sulphamethoxazole.
This study revealed the emergence of saprophytic bacteria as potential drug-resistant nosocomial pathogens in Ethiopian patients with cancer. As these pathogens are ubiquitous in the environment, infection prevention actions should be strengthened in the hospital and early diagnosis and treatment with appropriate antibiotics are warranted for those already infected.
近年来,腐生菌已逐渐成为可导致恶性肿瘤患者发生危及生命感染的潜在人类病原体。然而,关于此类细菌的证据却很缺乏,尤其是在撒哈拉以南国家。本研究旨在确定埃塞俄比亚一家转诊医院中导致发热癌症患者血流感染(BSIs)的罕见细菌病原体的种类及耐药情况。
2011年12月至2012年6月期间,从提古雷·安贝萨医院的107例癌症患者中采集血样。使用血培养瓶和固体培养基进行培养,并通过革兰氏染色和APINE鉴定试剂盒(法国生物梅里埃公司)鉴定微生物。采用纸片扩散法进行药敏试验。
总体而言,在接受调查的107例成年发热癌症患者中,分离出13种(12.2%)罕见的人类病原体。 菌属(一种发酵革兰氏阴性杆菌)是主要分离菌,占30.8%(4/13),其次是 菌属占15.4%(2/13), 菌属占15.4%(2/13), 菌属占15.4%(2/13)。在对9种抗生素进行测试的9株分离菌中,89%对阿莫西林 - 克拉维酸、氨苄西林和甲氧苄啶 - 磺胺甲恶唑耐药。
本研究揭示了腐生菌在埃塞俄比亚癌症患者中作为潜在耐药医院病原体的出现。由于这些病原体在环境中普遍存在,应加强医院的感染预防措施,对于已感染患者,有必要尽早使用适当抗生素进行诊断和治疗。